Patents by Inventor Lori F. Rafield

Lori F. Rafield has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Retroviral gene therapy vectors and therapeutic methods based thereon
    Patent number: 6544771
    Abstract: Retroviral vectors are disclosed which include an insertion site for genes of interest and are capable of expressing high levels of the protein derived from the genes of interest in a wide variety of transfected cell types. Also disclosed are retroviral vectors lacking a selectable marker, thus rendering them suitable for human gene therapy in the treatment of a variety of disease states without the co-expression of a marker product, such as an antibiotic. These retroviral vectors are especially suited for use in certain packaging cell lines.
    Type: Grant
    Filed: June 2, 1994
    Date of Patent: April 8, 2003
    Assignees: Cell Genesys, Inc., Whitehead Institute for Biomedical Research
    Inventors: Isabelle Rivière, Lawrence K. Cohen, Brad Guild, Lori F. Rafield, Paul Robbins, Richard C. Mulligan
  • Retroviral gene therapy vectors and therapeutic methods based thereon
    Patent number: 6140111
    Abstract: Retroviral vectors are disclosed which include an insertion site for genes of interest and are capable of expressing high levels of the protein derived from the genes of interest in a wide variety of transfected cell types. Also disclosed are retroviral vectors lacking a selectable marker, thus rendering them suitable for human gene therapy in the treatment of a variety of disease states without the co-expression of a marker product, such as an antibiotic. These retroviral vectors are especially suited for use in certain packaging cell lines.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: October 31, 2000
    Assignees: Whitehead Institute for Biomedical Research, Cell Genesys, Inc.
    Inventors: Isabelle Riviere, Lawrence K. Cohen, Brad Guild, Lori F. Rafield, Paul Robbins, Richard C. Mulligan
  • Genetic modification of endothelial cells
    Patent number: 5674722
    Abstract: Endothelial cells transduced with genetic material encoding a polypeptide or protein of interest and, optionally, a selectable marker, as well as methods for making and using the transduced endothelial cells are disclosed. Such endothelial cells are useful in improving the performance of vascular grafts and in delivering the encoded polypeptide or protein, such as an enzyme, a hormone, a receptor or a drug, to an individual.
    Type: Grant
    Filed: May 25, 1994
    Date of Patent: October 7, 1997
    Assignees: Somatix Therapy Corporation, Whitehead Institute For Biomedical Research, Brigham & Womens Hospital, Howard Hughes Medical Institute, New England Medical Center Hospitals
    Inventors: Richard C. Mulligan, Lawrence K. Cohen, Lori F. Rafield, Louis K. Birinyi, Allan D. Callow, James M. Wilson